COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Adjuvant Gemcitabine and Cisplatin Followed by Chemoradiation for Resected Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01396681
Recruitment Status : Completed
First Posted : July 19, 2011
Last Update Posted : July 19, 2011
Information provided by:
Seoul National University Hospital

Brief Summary:
This is a phase Ⅱ Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Gemcitabine in Patients With Resected Pancreatic Cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: gemcitabine and cisplatin Phase 2

Detailed Description:
The primary study objective is to evaluate recurrence/metastasis free survival at 12 months with postoperative adjuvant treatment incorporating gemcitabine plus cisplatin chemotherapy followed by chemoradiation with gemcitabine followed by maintenance chemotherapy with gemcitabine.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ⅱ Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Gemcitabine in Patients With Resected Pancreatic Cancer
Study Start Date : December 2004
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Intervention Details:
  • Drug: gemcitabine and cisplatin
    The study consists of three phases; Induction chemotherapy phase:Starting 4~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles

Primary Outcome Measures :
  1. recurrence/metastasis free survival [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. 2 year survival rate [ Time Frame: 24 months ]
  2. Overall survival [ Time Frame: 24 months ]
  3. recurrence free survival [ Time Frame: 24 months ]
    Median recurrence free survival time

  4. Safety and tolerability [ Time Frame: 24 months ]
    patients who experienced grade 3-4 toxicity by RECIST criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Give written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.
  2. Be between 18 and 75 years of age.
  3. Patients who are ambulatory and have a ECOG Performance Status of 0-2.
  4. Histologically confirmed pancreatic adenocarcinoma.
  5. Received curative resection (R0 resection) of stage 1b ~ 2b pancreatic cancer (according to AJCC staging, 6th edition - Appendix 1), no more than 8 weeks has elapsed since the time of operation.
  6. WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3. Platelet count at least 100,000/mm3.
  7. Bilirubin less than 2.0 mg/dL, AST less than 3 times upper limit of normal (ULN).

Serum creatinine no greater than 1.5 times ULN.

Exclusion Criteria:

  1. Pregnant or lactating woman.
  2. Woman of childbearing potential with either a positive or no pregnancy test at baseline.
  3. Woman of childbearing potential not using a reliable and appropriate contraceptive method (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).
  4. Sexually active males unwilling to practice contraception during the study.
  5. Prior chemotherapy for the treatment of pancreatic carcinoma.
  6. Radiotherapy incorporating radiation fields of more than 25% of active bone marrow.
  7. History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
  8. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication).
  9. Participation in any investigational drug study within four weeks preceding the start of study treatment.
  10. Serious, uncontrolled, intercurrent infection(s).
  11. Other significant medical conditions that would, in the judgment of the investigator, make administration of study drug unsafe.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01396681

Layout table for location information
Korea, Republic of
Seoul National University Bundang Hospital
Seongnam, Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Seoul National University Hospital
Layout table for investigator information
Principal Investigator: Seock-Ah Im, MD, PhD Seoul National University Hospital
Layout table for additonal information
Responsible Party: Seock-Ah Im, Seoul National University Hospital Identifier: NCT01396681    
Other Study ID Numbers: H-0412-138-006
First Posted: July 19, 2011    Key Record Dates
Last Update Posted: July 19, 2011
Last Verified: July 2011
Keywords provided by Seoul National University Hospital:
resected pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs